MedTrace Logo

Chest CT Using Low-concentration Iodine Contrast Media

NCT05967117 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 370

Last updated 2024-07-25

No results posted yet for this study

Summary

This study aims to evaluate the quality of images when low-concentration iodine contrast agents is used in chest CT with low tube voltage and if they can be used in routine imaging.

The primary endpoint of the study was the quality of the image and comparison of chest CT by using low and conventional concentration iodine contrast agents with low tube voltage and chest CT by using the conventional concentration iodine contrast agents with the conventional tube voltage; The secondary endpoint is optimizing chest CT protocol using an iodine contrast agent.

Conditions

  • Pulmonary Disease

Interventions

DRUG

Iohexol (320mgI/mL) with 120kVp

Patient undergoing CT scan with 120kVp protocol and using Iobrix inj. 320 (Taejoon pharm, Seoul, South Korea). CT images were obtained 55sec after Contrast media injection(100mL, 2mL/sec) with 20mL saline flushing.

DRUG

Iohexol (320mgI/mL) with 100kVp

Patient undergoing CT scan with 100kVp protocol and using Iobrix inj. 320 (Taejoon pharm, Seoul, South Korea). CT images were obtained 55sec after Contrast media injection(100mL, 2mL/sec) with 20mL saline flushing.

DRUG

Iohexol (270mgI/mL) with 100kVp

Patient undergoing CT scan with 100kVp protocol and using Iobrix inj. 270 (Taejoon pharm, Seoul, South Korea). CT images were obtained 55sec after Contrast media injection(100mL, 2mL/sec) with 20mL saline flushing.

DRUG

Iohexol (240mgI/mL) with 100kVp

Patient undergoing CT scan with 100kVp protocol and using Iobrix inj. 240 (Taejoon pharm, Seoul, South Korea). CT images were obtained 55sec after Contrast media injection(100mL, 2mL/sec) with 20mL saline flushing.

Sponsors & Collaborators

  • Taejoon Pharmaceutical Co., Ltd.

    collaborator INDUSTRY

  • Jung Im Jung

    lead OTHER

Principal Investigators

  • Jung Im Jung, MD, PhD · Seoul St. Mary's Hospital

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-11-24
Primary Completion
2024-11-30
Completion
2024-11-30

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05967117 on ClinicalTrials.gov